Hologic Q1 revenue misses estimates

Hologic

29/01/2026 21:12

Overview

Medical technology firm's Q1 revenue grew 2.5% yr/yr, missing analyst expectations

Adjusted EPS for Q1 increased 1.0% but missed analyst expectations

Company scheduled special stockholder meeting for merger vote with funds managed by Blackstone and TPG

Outlook

Hologic is not providing fiscal 2026 guidance due to pending acquisition by Blackstone and TPG

Result Drivers

SURGICAL SEGMENT - Revenue grew 8.7%, driven by increased sales from the acquired Gynesonics business and products like MyoSure and Fluent

BREAST HEALTH - Revenue rose 1.8%, supported by strong sales of Endomagnetics products

DIAGNOSTICS DECLINE - Revenue decreased 1.3%, impacted by lower sales of COVID-19 tests and legacy assays

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Miss
$1.05 bln
$1.07 bln (8 Analysts)
Q1 Adjusted EPS
Miss
$1.04
$1.09 (10 Analysts)
Q1 EPS
$0.79
Q1 Adjusted Net Income
Miss
$235.50 mln
$247.62 mln (7 Analysts)
Q1 Adjusted EBITDA
Miss
$330.40 mln
$338.50 mln (4 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 18 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."

Wall Street's median 12-month price target for Hologic Inc is $76.00, about 1.2% above its January 28 closing price of $75.10

The stock recently traded at 16 times the next 12-month earnings vs. a P/E of 15 three months ago

Press Release: ID:nBwbH1JNga

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)